Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from October 29, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 27, 2026 — +6.8% at the close.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$65.72 Published $79.52 Target $70.22 Window close $75.59 Peak
$65.00 – $66.00Entry zone — fair-value band
$65.72Published — price the day we called it
$79.52Target — the price the thesis aimed for
$75.59Peak — highest point inside the window, not a realized return
$70.22Window close — end-of-window price, context only

What happened

Partial

Reached 71% of the predicted growth at its peak, without hitting the target.

At window close
+6.8%
realized, from the publication price to the last close inside the window
Peak gain
+15%
peak, from the publication price — not a realized return
S&P 500, same window
+1.5%
SPY over the identical days, dividend-adjusted
Window close
$70.22
last close inside the window, ended January 27, 2026
Peak price
$75.59
peak on January 7, 2026 — not a realized return
Days to target
—

The thesis — published October 29, 2025

Predicted growth
+21%
over the measurement window
Target price
$79.52
the price the thesis aimed for
Entry zone
$65.00 – $66.00
the fair-value band we waited for
Price at publication
$65.72
published October 29, 2025
Confidence
73%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Halozyme mixes solid business trends with a stock that looks washed out. Its ENHANZE drug-delivery royalties keep profits healthy, and a well-known firm repeated its Buy view with a $90 goal before the Nov 3 report. The price has fallen hard, and early signs point to momentum improving. Over the next 0-3 months, results could change the mood. Buying near $65-$66 aims to catch a bounce while keeping earnings-day risk in check.

Primary drivers

  • Growing royalty fees from ENHANZE support steady and improving margins
  • Nov 3 earnings report could shift investor views and reset sentiment
  • Analyst reaffirms Buy rating with a $90 price target, supporting upside
  • Share price looks beaten down, raising odds of a near-term rebound

How it played out

HALO: thesis partly played out, target missed

Lyra published HALO on 2025-10-29 at $65.72 for a short-term window through 2026-01-27. The thesis looked for 21% growth. It pointed to ENHANZE royalty fees, the Nov. 3 earnings report, a Buy view with a $90 goal, and a beaten-down share price that could rebound near $65 to $66.

The stock rose, but not enough. HALO peaked at $75.59 on 2026-01-07, a 15% gain, while the target was $79.52. It never got there. By 2026-01-27, it ended at $70.22. The thesis partly played out because the rebound happened, but the published target was missed.

What happened during the window

On Nov. 3, Halozyme reported third-quarter results. Investors Business Daily later wrote that profit was $1.72 a share and revenue was $354 million, and that management raised its full-year 2025 guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals